NCT06744075View on ClinicalTrials.gov

Study of the Clearance of Minimal Residual Disease Measured At the End of First-line Treatment in Patients with Lymphoma

NANot yet recruitingINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2027

Conditions

B-cell LymphomaHodgkin Lymphoma

Interventions

OTHER

Blood assessment

ctDNA collection (venous blood draw) will occur at baseline, mid-treatment, and at the end of treatment

Trial Locations (2)

76038

Centre Henri Becquerel, Rouen

76290

Hôpital Jacques Monod, Montivilliers

All Listed Sponsors

lead

Centre Henri Becquerel

OTHER

NCT06744075 - Study of the Clearance of Minimal Residual Disease Measured At the End of First-line Treatment in Patients with Lymphoma | Biotech Hunter | Biotech Hunter